Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Other financing activities (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Other financing activities for 4 consecutive years, with -$457600.0 as the latest value for Q4 2024.

  • Quarterly Other financing activities changed N/A to -$457600.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$409513.0 through Dec 2024, down 670.86% year-over-year, with the annual reading at $448279.0 for FY2025, N/A changed from the prior year.
  • Other financing activities hit -$457600.0 in Q4 2024 for Pasithea Therapeutics, down from $24175.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $299665.0 in Q2 2021 to a low of -$836150.0 in Q4 2021.
  • Historically, Other financing activities has averaged -$82486.3 across 4 years, with a median of $23912.0 in 2022.
  • Biggest YoY gain for Other financing activities was 91.07% in 2022; the steepest drop was 92.02% in 2022.
  • Year by year, Other financing activities stood at -$836150.0 in 2021, then skyrocketed by 91.07% to -$74627.0 in 2022, then surged by 132.39% to $24175.0 in 2023, then tumbled by 1992.86% to -$457600.0 in 2024.
  • Business Quant data shows Other financing activities for KTTA at -$457600.0 in Q4 2024, $24175.0 in Q3 2023, and $23912.0 in Q2 2023.